Mostrar el registro sencillo del ítem

dc.contributor.advisorAndrade, Saulo Fernandes dept_BR
dc.contributor.authorFortes, Isadora Serragliopt_BR
dc.date.accessioned2022-01-20T04:38:29Zpt_BR
dc.date.issued2018pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/234265pt_BR
dc.description.abstractIt has previously been found a potent 2,3,4-oxazolidine series which was synthetized using the amino acid D-serine as the starting material. These compounds were assayed against cancer cell lines (HL60, JURKAT, LNCaP, MDA-MB-231, MCF-7, HCT-116) and their structure−activity relationship were investigated. The purpose of this work was to synthetize through seven steps, characterize and evaluate four 2,3,4-oxazolidines analogues against DAOY, SK-N-BE(2) and RD-ES pediatric cell lines. Compounds 5a and 5b designed by the extension of the structure of 1 were the most potent, being active against all cell lines (IC50 ≤ 7 μM) and reduced ≥ 90% of cell viability at 25 μM for RD-ES and SK-N-BE(2). These derivatives were identified as novel anticancer agents including the novel direction towards pediatric cancer cells.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.rightsOpen Accessen
dc.subjectCâncerpt_BR
dc.subjectPediatric canceren
dc.subjectAnti-canceren
dc.subjectOxazolidinonaspt_BR
dc.subjectSynthesisen
dc.subjectOxazolidinesen
dc.subjectChiralen
dc.titleSynthesis and evaluation of 2,3,4-substituted chiral oxazolidines against pediatric cancer cellspt_BR
dc.typeTrabalho de conclusão de graduaçãopt_BR
dc.contributor.advisor-coRocha, Débora Assumpçãopt_BR
dc.identifier.nrb001094673pt_BR
dc.degree.grantorUniversidade Federal do Rio Grande do Sulpt_BR
dc.degree.departmentFaculdade de Farmáciapt_BR
dc.degree.localPorto Alegre, BR-RSpt_BR
dc.degree.date2018pt_BR
dc.degree.graduationFarmáciapt_BR
dc.degree.levelgraduaçãopt_BR


Ficheros en el ítem

Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem